Jinghua Pharmaceutical Group Co., Ltd. (SHE:002349)

Market Cap	5.67B
Revenue (ttm)	1.40B
Net Income (ttm)	203.79M
Shares Out	814.18M
EPS (ttm)	0.25
PE Ratio	27.81
Forward PE	n/a
Dividend	0.09 (1.32%)
Ex-Dividend Date	Jun 12, 2024

Volume	6,095,000
Average Volume	9,369,840
Open	7.10
Previous Close	6.91
Day's Range	6.90 - 7.10
52-Week Range	6.31 - 9.34
Beta	0.18
RSI	43.46
Earnings Date	Apr 15, 2025

About SHE:002349

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and is based in Nantong, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1957
• Employees: 1,493
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002349

Financial Performance

In 2024, SHE:002349's revenue was 1.40 billion, a decrease of -7.25% compared to the previous year's 1.51 billion. Earnings were 212.65 million, a decrease of -14.15%.